Prescription & OTC Drugs

Sterne Kessler’s pharmaceuticals team helps small molecule drug companies across the full range of IP – patents, litigation, opinions and strategy.

Sterne Kessler helps ethical drug companies to develop robust, defensible patent portfolios that create substantial shareholder value over the entire lifecycle of a drug. That work includes patents defending fundamental, breakthrough inventions as well as follow-on patents supporting product manufacturing, methods of use and FDA approved labeling.

In today’s competitive landscape, strong patent protection is critical in bringing pharmaceuticals to market. We understand the challenges and risks clients face, so we focus on providing high-value counseling. Ultimately, a strategy is only as good as its execution. Our attorneys and agents have drafted and prosecuted hundreds of patent applications for small molecule pharmaceuticals. We’ve also developed expertise in identifying additional patentable inventions as a new chemical entity works its way through the development process.

We represent institutions involved in the development of:

  • New chemical entities
  • New methods of chemical synthesis
  • Drug design platforms
  • Drug screening and assays
  • Formulations
  • New therapeutic methods
  • In vivo diagnostics
  • Medical imaging and contrast agents

In many instances, technology commercialization in the pharmaceutical industry requires multiple technical disciplines. Our deeply experienced ethical drug team extends to related technical areas, including:

  • Medical devices
  • Computer-aided drug discovery
  • Bioinformatics
  • Biodefense

For those collaborating, licensing or commercializing innovations, we provide counseling regarding agreements and freedom to operate in the marketplace. Additionally, we conduct intellectual property due diligence to support those who are licensing or investing in promising new technologies. Finally, we have a leading ANDA litigation practice and support branded drug companies in high-stakes Hatch-Waxman litigation.

Related Resources

In the News

Petition Watch: Patent Obviousness, ADA Trials, Spoofing

Law360 January 25, 2024

In the News

Teva Defeats Infringement Claims on Endocrine Drug

New Jersey Law Journal January 3, 2024

Firm Announcements

Sterne Kessler Secures Non-Infringement Win for Teva Pharmaceuticals

Sterne, Kessler, Goldstein & Fox January 3, 2024

Press Release

Ivy Estoesta Recognized as an INTA Rising Star

Sterne, Kessler, Goldstein & Fox November 1, 2023

Speaking Engagement

FDA and PTO Panel

July 1, 2023 9:45 AM - 10:45 AM PST

Speaking Engagement

Roundtable Discussion Group: Patentability of Diagnostic Techniques

May 4, 2023 11:45 AM - 1:20 PM PST

Speaking Engagement

Chairman’s Opening Address and Closing Remarks

May 3, 2023 9:00 AM - 5:00 PM PST

Speaking Engagement

2023 Focus on Pharma

April 14, 2023 8:30 AM - 6:00 PM PST

Webinar

Patent Term Extensions for Pharma Products in Europe and the USA

March 15, 2023 11:00 AM - 12:00 PM PST

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox January 30, 2023

MarkIt to Market®

MarkIt to Market® – January 2023

January 30, 2023

Speaking Engagement

Patents in the Cross-Hairs of the Affordable Drug Conversation

December 5, 2022 9:30 AM - 10:30 AM PST

Speaking Engagement

Chairman’s Opening Address and Closing Remarks

May 11, 2022 9:00 AM - 4:45 PM PST

In the News

ImmunoGen Patent Application Suit Sent Back to Court (1)

Bloomberg Law March 25, 2022

MarkIt to Market®

MarkIt to Market® – February 2022

February 25, 2022

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox February 25, 2022

MarkIt to Market®

MarkIt to Market® – December 2021

December 22, 2021

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox December 22, 2021

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox December 22, 2021

In the News

USPTO Faces Growing Pressure To Enter Battle Over Drug Pricing

Pink Sheet September 23, 2021

In the News

Teva Win on Three Migraine Drug Patents, Losses on Six Upheld

Bloomberg Law August 16, 2021

In the News

Adapt Faces Tough Questions in Bid to Revive Narcan Patents

Bloomberg Law August 2, 2021

In the News

IP Forecast: Fed. Circ. To Mull Narcan Patents

Law360 July 29, 2021

MarkIt to Market®

MarkIt to Market® – March 2021

March 31, 2021

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox P.L.L.C. March 31, 2021

Bylined Articles

GW Pharma Seeks Dismissal of Patent Suit Filed in Texas by Canopy Growth

Sterne, Kessler, Goldstein & Fox P.L.L.C. March 31, 2021

Press Release

Sterne Kessler Named Among 2021 “Best Law Firms” by Best Lawyers

Sterne, Kessler, Goldstein & Fox November 6, 2020

In the News

Justices Skip Case Horizon Said Puts 32K Patents At Risk

Law360 November 3, 2020

Webinar

Drug Development Pathway Series: Intellectual Property Workshop

October 28, 2020 4:00 PM - 5:00 PM PST

Press Release

Firm and Seven Directors Recognized in 2020 LMG Life Sciences Rankings

Sterne, Kessler, Goldstein & Fox P.L.L.C. October 6, 2020

In the News

In Case You Missed It: Hottest Firms And Stories On Law360

Law360 September 11, 2020

Bylined Articles

Patent License Considerations After Fed. Circ. Enbrel Ruling

Law360 September 4, 2020

In the News

Pandemic Lays Bare Fight Over Patent Strength, Innovation

Bloomberg Law August 11, 2020

In the News

Teva Invalidates Opiant Patents In Narcan Suit

Law360 June 5, 2020

Bylined Articles

Vaccine R&D and Economic Impact of COVID-19 Pandemic

ACC Docket April 22, 2020

Webinar

Innovation in the Age of COVID-19

April 14, 2020 11:00 AM - 1:00 PM PST

In the News

Webinar on Innovation in Age of COVID-19

Patent Docs April 11, 2020

Bylined Articles

Patenting Compounds, Compositions, and Methods for Viral Infections

Bloomberg Law March 11, 2020

Speaking Engagement

Pharma IPR Conference 2020

March 4, 2020 12:00 AM - 11:59 PM PST

Bylined Articles

Vaccine IP Under Microscope With Coronavirus Outbreak

Law360 March 4, 2020

In the News

Federal Circuit Ruling Could Put Certain Drug Patents At Risk

Bloomberg Law December 31, 2019

In the News

Teva Gets PTAB To Review Cushing’s Syndrome Drug Patent

Law360 November 21, 2019

In the News

PTAB Cuts Down Two More Allergan Restasis Patents

Law360 September 30, 2019

Speaking Engagement

MIP Life Sciences Forum 2019

September 18, 2019

Bylined Articles

Proposed BPCIA reforms: More music, same dance

Managing Intellectual Property May 16, 2019

Speaking Engagement

13th Annual Paragraph IV Disputes

April 29, 2019

In the News

Fed. Circ. Won’t Revisit Restasis Patent Ruling

Law360 March 6, 2019

Bylined Articles

Federal Circuit Issues Further Guidance On AIA Proceeding Standing To Appeal

Sterne, Kessler, Goldstein & Fox P.L.L.C February 22, 2019

Speaking Engagement

Access! 2019 – AAM Annual Meeting

February 4, 2019

PTAB Strategies and Insights

PTAB Strategies and Insights – January 2019

January 24, 2019

Bylined Articles

PTAB Only Partially Smokes Cannabis Patent

Sterne, Kessler, Goldstein & Fox P.L.L.C. January 24, 2019

Bylined Articles

What Cannabis Patent Applicants Can Learn From Biopharma

Law360 January 17, 2019

In the News

3 Takeaways From The PTAB’s Cannabis Experience

Law360 January 11, 2019

In the News

J&J Tells Fed. Circ. Judge Was Wrong To Nix Zytiga Patent

Law360 December 4, 2018

In the News

Fed. Circ. Urged Not to Stay Immunity Ruling for Appeal

Law360 November 6, 2018

Speaking Engagement

Microbiome R&D and Business Collaboration Forum: USA

October 29, 2018 12:00 AM - 11:59 PM PST

In the News

No Need To Reconsider Immunity At PTAB, Fed. Circ. Hears

Law360 September 19, 2018

In the News

Generics Cos. Urge Fed. Circ. To Upend Depomed Patent Win

Law360 September 4, 2018

In the News

Fed. Circ. Impeding Biopharma Innovation, Justices Told

Law360 August 29, 2018

Speaking Engagement

Clinical Innovation: Fair and Effective Incentives for New Uses of Established Drugs

February 8, 2018 8:30 AM - 5:30 PM PST

In the News

Patent Cases To Watch In 2018

Law360 January 1, 2018

In the News

Judge Hacks Away At Allergan’s Restasis Patents

Law360 October 18, 2017

Bylined Articles

Divided Infringement After Eli Lilly V. Teva

Law360 April 18, 2017

Bylined Articles

Top 5 PTAB Tips for Big Pharma

New Jersey Law Journal April 3, 2017